CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: AFMID (ImmuneEditome ID:125061)

1. Gene summary of enriched editing regions for AFMID

check button Gene summary
Gene informationGene symbol

AFMID

Gene ID

125061

GeneSynonymsFKF|KF|KFA
GeneCytomap

17q25.3

GeneTypeprotein-coding
GeneDescriptionkynurenine formamidase|KFase|N-formylkynurenine formamidase|probable arylformamidase
GeneModificationdate20230329
UniprotIDQ63HM1;W4VSQ7;K7EPF8;K7EMI4;K7EIX3;K7EMM5;K7ELV9;K7EK09;K7EQK5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:78187741-78187922:+ENST00000592988.4ENSG00000183077.14AFMIDncRNA_intronicAluSgchr17:78187741-78187922:+.alignment
chr17:78191425-78196683:+ENST00000589107.4ENSG00000183077.14AFMIDexonicAluSz,L1MB3,AluSq2,AluSz6,AluJr,AluSc,AluY,AluSp,A-richchr17:78191425-78196683:+.alignment
chr17:78197872-78204391:+ENST00000327898.8ENSG00000183077.14AFMIDexonicMLT1C,(AAAAC)n,MIR,AluY,AluSx1,AluJr4,AluJb,AluJo,AluSx,AluSz6,AluSx3,L1ME4b,AluSz,AluSq2,MER81chr17:78197872-78204391:+.alignment
chr17:78197872-78204391:+ENST00000409257.8ENSG00000183077.14AFMIDexonicMLT1C,(AAAAC)n,MIR,AluY,AluSx1,AluJr4,AluJb,AluJo,AluSx,AluSz6,AluSx3,L1ME4b,AluSz,AluSq2,MER81chr17:78197872-78204391:+.alignment
chr17:78197872-78204391:+ENST00000586542.4ENSG00000183077.14AFMIDexonicMLT1C,(AAAAC)n,MIR,AluY,AluSx1,AluJr4,AluJb,AluJo,AluSx,AluSz6,AluSx3,L1ME4b,AluSz,AluSq2,MER81chr17:78197872-78204391:+.alignment
chr17:78197872-78204391:+ENST00000588199.4ENSG00000183077.14AFMIDexonicMLT1C,(AAAAC)n,MIR,AluY,AluSx1,AluJr4,AluJb,AluJo,AluSx,AluSz6,AluSx3,L1ME4b,AluSz,AluSq2,MER81chr17:78197872-78204391:+.alignment
chr17:78197872-78204391:+ENST00000588800.4ENSG00000183077.14AFMIDexonicMLT1C,(AAAAC)n,MIR,AluY,AluSx1,AluJr4,AluJb,AluJo,AluSx,AluSz6,AluSx3,L1ME4b,AluSz,AluSq2,MER81chr17:78197872-78204391:+.alignment
chr17:78197872-78204391:+ENST00000591256.4ENSG00000183077.14AFMIDexonicMLT1C,(AAAAC)n,MIR,AluY,AluSx1,AluJr4,AluJb,AluJo,AluSx,AluSz6,AluSx3,L1ME4b,AluSz,AluSq2,MER81chr17:78197872-78204391:+.alignment
chr17:78206170-78207450:+ENST00000327898.8ENSG00000183077.14AFMIDexonicAluSz6,AluJb,AluSx4,(CTTCCTC)n,(TCT)nchr17:78206170-78207450:+.alignment
chr17:78206170-78207450:+ENST00000409257.8ENSG00000183077.14AFMIDexonicAluSz6,AluJb,AluSx4,(CTTCCTC)n,(TCT)nchr17:78206170-78207450:+.alignment
chr17:78206170-78207450:+ENST00000591952.4ENSG00000183077.14AFMIDexonicAluSz6,AluJb,AluSx4,(CTTCCTC)n,(TCT)nchr17:78206170-78207450:+.alignment


Top

2. Tumor-specific enriched editing regions for AFMID


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:78197872-78204391:+BRCAEER4.9507e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000183077.14,AFMIDCESCCliEAG1.0381e-038.2579e-030.5262image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for AFMID


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for AFMID


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for AFMID


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000183077.14,AFMIDBLCAEAGDendritic_cells_activated2.5476e-02-0.3292image
chr17:78191425-78196683:+BRCAEERNK_cells_activated1.0357e-02-0.1886image
ENSG00000183077.14,AFMIDCESCEAGEosinophils3.2770e-020.4281image
ENSG00000183077.14,AFMIDCOADEAGT_cells_CD4_memory_resting3.5706e-02-0.3562image
chr17:78191425-78196683:+ESCAEERT_cells_CD4_memory_activated4.1084e-020.2561image
chr17:78197872-78204391:+KIRCEERT_cells_gamma_delta4.7557e-030.2774image
ENSG00000183077.14,AFMIDKIRCEAGT_cells_gamma_delta5.8012e-030.2626image
chr17:78197872-78204391:+KIRPEERT_cells_CD81.5551e-020.2697image
ENSG00000183077.14,AFMIDKIRPEAGDendritic_cells_resting2.3526e-020.2441image
chr17:78197872-78204391:+LAMLEERT_cells_CD4_memory_resting1.1284e-02-0.2892image
ENSG00000183077.14,AFMIDLAMLEAGNK_cells_resting2.0613e-02-0.2465image
ENSG00000183077.14,AFMIDLGGEAGMonocytes5.3354e-030.4809image
chr17:78197872-78204391:+LIHCEERMast_cells_resting9.0174e-03-0.2058image
chr17:78206170-78207450:+LIHCEERT_cells_regulatory_(Tregs)2.7467e-02-0.3625image
ENSG00000183077.14,AFMIDLIHCEAGMast_cells_resting7.0969e-03-0.2064image
chr17:78197872-78204391:+LUADEERT_cells_gamma_delta8.5009e-040.3367image
chr17:78197872-78204391:+LUSCEERPlasma_cells4.0935e-020.2468image
chr17:78191425-78196683:+OVEERDendritic_cells_activated4.3418e-02-0.2264image
chr17:78206170-78207450:+OVEERT_cells_CD4_memory_activated2.9076e-020.2592image
ENSG00000183077.14,AFMIDOVEAGDendritic_cells_activated3.7562e-020.1646image
ENSG00000183077.14,AFMIDPAADEAGT_cells_CD81.0123e-020.5480image
chr17:78191425-78196683:+PRADEERT_cells_CD4_memory_resting2.1329e-02-0.3424image
chr17:78197872-78204391:+PRADEERMast_cells_activated1.7309e-020.2266image
chr17:78191425-78196683:+STADEERT_cells_CD83.7785e-030.2542image
chr17:78197872-78204391:+STADEERT_cells_CD82.4253e-030.2235image
ENSG00000183077.14,AFMIDSTADEAGT_cells_CD82.6702e-030.2034image


Top

6. Enriched editing regions and immune gene sets for AFMID


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000183077.14,AFMIDBLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG8.2687e-03-0.3849image
chr17:78197872-78204391:+BRCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER5.5302e-030.1531image
ENSG00000183077.14,AFMIDCESCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.6563e-020.4430image
chr17:78197872-78204391:+COADGSVA_HALLMARK_MITOTIC_SPINDLEEER6.4954e-03-0.5020image
ENSG00000183077.14,AFMIDCOADGSVA_HALLMARK_ANGIOGENESISEAG3.4116e-020.3591image
chr17:78206170-78207450:+ESCAGSVA_HALLMARK_ANGIOGENESISEER4.0097e-020.2534image
chr17:78197872-78204391:+ESCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.2438e-02-0.2051image
ENSG00000183077.14,AFMIDKIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.3574e-03-0.2786image
chr17:78197872-78204391:+KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.0671e-02-0.2518image
chr17:78191425-78196683:+KIRCGSVA_HALLMARK_MYC_TARGETS_V1EER1.8538e-02-0.5208image
ENSG00000183077.14,AFMIDKIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.7230e-020.2250image
chr17:78197872-78204391:+LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.4363e-020.2798image
ENSG00000183077.14,AFMIDLAMLGSVA_HALLMARK_MYOGENESISEAG3.1074e-02-0.2300image
ENSG00000183077.14,AFMIDLIHCGSVA_HALLMARK_PEROXISOMEEAG1.2930e-02-0.1909image
chr17:78206170-78207450:+LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.8749e-020.3846image
ENSG00000183077.14,AFMIDLUADGSVA_HALLMARK_SPERMATOGENESISEAG2.5206e-020.2078image
chr17:78197872-78204391:+LUADGSVA_HALLMARK_PEROXISOMEEER4.0072e-02-0.2110image
chr17:78206170-78207450:+LUSCGSVA_HALLMARK_MYC_TARGETS_V2EER2.0217e-03-0.5494image
chr17:78197872-78204391:+LUSCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.2503e-02-0.2744image
chr17:78191425-78196683:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5011e-02-0.2505image
chr17:78206170-78207450:+OVGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.4846e-020.2389image
ENSG00000183077.14,AFMIDPAADGSVA_HALLMARK_UV_RESPONSE_DNEAG3.4986e-030.6074image
ENSG00000183077.14,AFMIDPRADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.4537e-05-0.3730image
chr17:78197872-78204391:+PRADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.3929e-04-0.3355image
chr17:78191425-78196683:+PRADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.9484e-02-0.3081image
chr17:78197872-78204391:+STADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER7.0835e-030.1990image


Top

7. Enriched editing regions and drugs for AFMID


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000183077.14,AFMIDBLCALapatinibEAG1.6678e-050.5889image
ENSG00000183077.14,AFMIDBRCADocetaxelEAG2.1043e-030.1583image
chr17:78197872-78204391:+BRCAAG.014699EER2.1901e-040.2030image
chr17:78191425-78196683:+BRCAGW.441756EER1.2661e-020.1835image
ENSG00000183077.14,AFMIDCESCDasatinibEAG3.2300e-04-0.6609image
ENSG00000183077.14,AFMIDCOADMethotrexateEAG3.7120e-020.3537image
chr17:78191425-78196683:+ESCABleomycinEER1.7795e-03-0.3831image
ENSG00000183077.14,AFMIDESCABicalutamideEAG1.0497e-020.2300image
chr17:78197872-78204391:+ESCAJNK.Inhibitor.VIIIEER1.1818e-02-0.2404image
chr17:78206170-78207450:+ESCAEHT.1864EER1.8540e-02-0.2891image
ENSG00000183077.14,AFMIDKIRCGSK.650394EAG1.9032e-030.2942image
chr17:78191425-78196683:+KIRCCI.1040EER3.0305e-030.6280image
chr17:78197872-78204391:+KIRCAMG.706EER1.6936e-02-0.2360image
chr17:78197872-78204391:+KIRPCMKEER2.0034e-020.2596image
ENSG00000183077.14,AFMIDKIRPBosutinibEAG5.7253e-030.2956image
chr17:78197872-78204391:+LAMLCHIR.99021EER8.0298e-040.3765image
ENSG00000183077.14,AFMIDLAMLJNK.9LEAG4.5299e-030.2999image
ENSG00000183077.14,AFMIDLGGBI.2536EAG4.0340e-03-0.4943image
ENSG00000183077.14,AFMIDLIHCCEP.701EAG2.3353e-02-0.1744image
chr17:78206170-78207450:+LIHCAZD6482EER1.1362e-03-0.5140image
chr17:78197872-78204391:+LIHCCCT007093EER2.6318e-030.2363image
chr17:78197872-78204391:+LUADEHT.1864EER6.1689e-030.2791image
ENSG00000183077.14,AFMIDLUADABT.263EAG1.5756e-02-0.2257image
chr17:78206170-78207450:+LUSCBryostatin.1EER3.1280e-03-0.5297image
chr17:78197872-78204391:+LUSCAUY922EER8.7290e-030.3134image
chr17:78197872-78204391:+OVAZD.2281EER4.1704e-020.1847image
chr17:78191425-78196683:+OVCytarabineEER3.0684e-03-0.3270image
chr17:78206170-78207450:+OVBryostatin.1EER3.0199e-020.2574image
ENSG00000183077.14,AFMIDOVBIRB.0796EAG3.7825e-03-0.2277image
ENSG00000183077.14,AFMIDPRADMethotrexateEAG4.8835e-030.2473image
chr17:78197872-78204391:+PRADAG.014699EER3.0217e-02-0.2068image
chr17:78191425-78196683:+PRADDMOGEER5.1255e-030.4103image
ENSG00000183077.14,AFMIDSTADAZD7762EAG6.1188e-03-0.1860image
chr17:78191425-78196683:+STADAKT.inhibitor.VIIIEER6.6456e-04-0.2970image
chr17:78206170-78207450:+STADCCT007093EER7.9934e-03-0.3002image
chr17:78197872-78204391:+STADBMS.509744EER3.5793e-05-0.3013image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType